Microbubble and ultrasound radioenhancement of bladder cancer

British Journal of Cancer

Volumn 107, Issue 3, 2012, Pages 469-476

  Tran, W T ^a,b,c   Iradji, S ^b   Sofroni, E ^b   Giles, A ^b   Eddy, D ^c   Czarnota, G J ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

anti vascular therapy; apoptosis; bladder cancer; cell death; radiosensitizers; ultrasound

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLOOD FLOW; CANCER RADIOTHERAPY; CELL DEATH; CONTROLLED STUDY; DOPPLER FLOWMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MICROBUBBLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; VASCULAR FIBROSIS;

ANIMALS; CELL DEATH; CELL LINE, TUMOR; CONTRAST MEDIA; ENDOTHELIAL CELLS; HUMANS; LONGITUDINAL STUDIES; MALE; MICE; MICE, SCID; MICROBUBBLES; NEOVASCULARIZATION, PATHOLOGIC; RADIATION DOSAGE; RADIATION-SENSITIZING AGENTS; REGIONAL BLOOD FLOW; ULTRASONICS; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864347754     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.279     Document Type: Article

References (33)

1. Blakey DC, Westwood R, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumour activity of the novel vascular targeting agent ZD6126 in a panel of tumour models. Clin Cancer Res 8: 1974-1983
2. Cooney MM, van Heekcheren W, Bhakta S, Ortz J, Remick SC (2006) Drug insight: vascular disrupting agents and angiogenesis-novel approaches for drug delivery. Nature Clin Prac Oncol 12: 682-692
3. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ (2007) Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res 13(11): 3395-3402
4. Duda DG, Batchelor TT, Willett CG, Jain RK (2007) VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol Med 13(6): 223-230
5. Feron O (2004) Targeting the tumour vascular compartment to improve conventional cancer therapy. Trends Pharmacol Sci 25(10): 536-542
6. Fukumura D, Jain RK (2007) Tumour microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 101: 937-949
7. Gadgeel SM, LoRusso PM, Wozniak AJ, Wheeler C (2002) A dose-escalation study of the novel vascular-targeting agent ZD6126, in patients with solid tumors. Proc Am Soc Clin Oncol 21: 438
8. Goertz DE, Yu JL, Kerbel RS (2002) High Frequency Doppler Ultrasound Monitors the Effects of Antivascular Therapy on Tumor Blood Flow. Cancer Res 62: 6371-6375
9. Hamper UM, DeJong MR, Caskey CI, Sheth S (1997) Power Doppler imaging: clinical experience and correlation with color Doppler US and other imaging modalities. RadioGraphics 17: 499-513
10. Hayes AJ, Li LY, Lippman ME (1999) Antivascular therapy: a new approach to cancer treatment. Br Med J 318: 853-8553
11. Jain RK (2005) Normalization of tumour vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62
12. Jameson MB, Thompson PI, Baguely BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P (2003) Clinical aspects of a phase I trial of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88: 1844-1850
13. Karshafian R, Bevan PD, Williams R, Samac S, Burns PN (2009) Sonoporation by ultrasound activated microbubble contrast agents: effect of acoustic exposure parameters on cell membrane permeability and cell viability. Ultrasound Med Biol 35(5): 847-860
14. Klibanov AL (2006) Microbubble contrast agents: Targeted ultrasound imaging and ultrasound-assisted drug delivery applications. Invest Radiol 41(3): 354-362
15. Kobayashi N, Yasu T, Yamada S, Kudo N, Kuroki M, Kawakami M, Miyatake K, Saito M (2002) Endothelial cell injury in venule and capillary induced by contrast ultrasonography. Ultrasound Med Biol 28(7): 949-956
16. Kolesnick R, Fuks Z (2003) Radiation and ceramide-induced apoptosis. Oncogene 22: 5897-5906
17. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD (2001) Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumour xenografts. Cancer Res 61: 39-44
18. Nieder C, Wiedenmann N, Andratschke N, Molls M (2006) Current status of angiogenesis inhibitors combined with radiation therapy. Cancer Tretment Rev 32: 348-364
19. Nishida N, Yano H, Nishida T, Kamura T, Kojiro M (2006) Angiogenesis in cancer. Vasc Health Risk Manage 2(3): 213-219
20. O'Reilly MS (2006) Radiation combined with Antiangiogenic and Antivascular Agents. Semin Radiat Oncol 16: 45-50
21. Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R, Yacoub A, Duigou GJ, Young CS, Grant S, Hagan MP, Ellis E, Fisher PB, Dent P (2001) Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways. Oncogene 20: 3266-3280
22. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C, Kolesnick R (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293: 293-297
23. Raben D, Ryan A (2005) Vascular-targeting agents and radiation therapy in lung cancer: Where do we stand in 2005? Clin Lung Cancer 7(3): 175-179
24. Radema SA, Beerepoot LV, Witteveen PO, Gebbink MF, Wheeler C, Voest EE (2002) Clinical evaluation of the novel vascular-targeting agent ZD6126: assessment of toxicity and surrogate markers of vascular damage. Proc Am Soc Clin Oncol 21: 439
25. Red-Horse K, Ferrara N (2006) Imaging tumour angiogenesis. J Clin Invest 116: 2585-2587
26. Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G (2003) 5,6-dimethylxanthenone-4- acetic-acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88: 1160-1167
27. Thomlinson RH (1973) Radiation and the vascularity of tumours. Br Med Bull 29(1): 29-32
28. Tiecher BA, Dupuis N, Kusomoto T, Robinson MF, Liu F, Menon K, Coleman CN (1994) Antiangiogenic agents can increase tumour oxygenation response to radiation therapy. Radiat Oncol Invest 2(6): 269-276
29. Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10: 415-427
30. Wachsberger P, Burd R, Dicker AP (2003) Tumour response to ionising radiation combined with antiangiogenesis or vascular targeting agents: Exploring mechanisms of interaction. Clin Cancer Res 9: 1957-1971
31. Xie F, Tsutsi JM, Lof J, Unger EC, Johanning J, Culp WC, Matsunaga T, Porter TR (2005) Effectiveness of lipid microbubbles and ultrasound in declotting thrombosis. Ultrasound Med Biol 31(7): 979-985
32. Xuan JW, Bygrave M, Jiang H, Valiyeva F, Dunmore-Buyze J, Holdsworth DW, Izawa JI, Bauman G, Moussa M, Winter SF, Greegnberg NM, Chin JL, Drangova M, Fenster A, Lacefield JC (2007) Functional neoangiogenesis imaging of genetically engineered mouse prostate cancer using three dimensional power doppler ultrasound. Cancer Res 67(6): 2830-2839
33. Yu T, Wang G, Hu K, Ma P, Bai J, Wang Z (2004) A microbubble agent improves the therapeutic efficiency of high intensity focused ultrasound: a rabit kidney study. Urol Res 32: 14-19